{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:55:05Z","timestamp":1793656505594,"version":"4.5.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["mcpiqojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings: Innovations, Quality & Outcomes"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.mayocpiqo.2025.100682","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T13:09:54Z","timestamp":1765372194000},"page":"100682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Operationalizing Access for Chimeric Antigen Receptor T cell Therapies: A Cross-functional Perspective"],"prefix":"10.1016","volume":"10","author":[{"given":"Surya","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Greulich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Terrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Walz-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4055-1338","authenticated-orcid":false,"given":"Michael D.","family":"Dalzell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mayocpiqo.2025.100682_bib1","article-title":"Approved CAR-T therapies have reproducible efficacy and safety in clinical practice","volume":"20","author":"Vera","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.mayocpiqo.2025.100682_bib4","author":"Liu"},{"issue":"16","key":"10.1016\/j.mayocpiqo.2025.100682_bib5","first-page":"1800","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study Blood","volume":"130","author":"Crump","year":"2017"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2025.100682_bib6","first-page":"166","article-title":"Treatment of relapsed\/refractory acute lymphoblastic leukemia","volume":"17","author":"Paul","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2025.100682_bib7","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/bloodadvances.2024014171","article-title":"Access barriers for anti-CD19+ chimeric antigen receptor T (CAR-T) cell therapy for non-Hodgkin lymphoma (NHL) across a large community transplant and cellular therapy network","volume":"9","author":"Battiwalla","year":"2025","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2025.100682_bib8","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jval.2022.02.007","article-title":"Value of reducing wait times for chimeric antigen receptor T-cell treatment: evidence from randomized controlled trial data on tisagenlecleucel for diffuse large B-Cell lymphoma","volume":"25","author":"Chen","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.mayocpiqo.2025.100682_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.19.00086","article-title":"Impact of increasing wait times on overall mortality of chimeric antigen receptor T-Cell therapy in large B-cell lymphoma: a discrete event simulation model","volume":"3","author":"Tully","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"issue":"suppl 3","key":"10.1016\/j.mayocpiqo.2025.100682_bib10","first-page":"11","article-title":"Anti-CD19 CAR T-cell therapy for adult patients with refractory large B-cell lymphoma","volume":"10","author":"McDermott","year":"2019","journal-title":"J Adv Pract Oncol"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2025.100682_bib12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jtct.2023.01.021","volume":"29","author":"Nikiforow","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.mayocpiqo.2025.100682_bib14","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.bbmt.2019.06.035","article-title":"Integration of publicly reported center outcomes into standards and accreditation: the FACT model","volume":"25","author":"LeMaistre","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.mayocpiqo.2025.100682_bib15","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.jtct.2024.07.011","article-title":"In pursuit of optimal outcomes: a framework for quality standards in immune effector cell therapy","volume":"30","author":"Dandoy","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.mayocpiqo.2025.100682_bib16","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jtct.2023.04.003","article-title":"Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"29","author":"Hoffman","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"2 suppl","key":"10.1016\/j.mayocpiqo.2025.100682_bib17","article-title":"From referral to product infusion, what are the barriers to CAR T-cell therapy? an academic center's comprehensive overview","volume":"30","author":"Terrell","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2025.100682_bib18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40290-022-00428-w","article-title":"Barriers to chimeric antigen receptor T-Cell (CAR-T) therapies in clinical practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharmaceutical Med"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2025.100682_bib19","first-page":"70","article-title":"Barriers to CAR T-cell therapy for LBCL challenge physicians and patients","volume":"1","author":"Feldman","year":"2023","journal-title":"Peers & Perspectives in Oncology"},{"issue":"11","key":"10.1016\/j.mayocpiqo.2025.100682_bib20","doi-asserted-by":"crossref","first-page":"1082.e1","DOI":"10.1016\/j.jtct.2024.09.007","article-title":"Real-world analysis of barriers to timely administration of chimeric antigen receptor T Cell (CAR T) therapy in diffuse large B-cell lymphoma","volume":"30","author":"Hu","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.mayocpiqo.2025.100682_bib21","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jtct.2022.09.020","article-title":"The ASTCT-NMDP ACCESS Initiative: a collaboration to address and sustain equal outcomes for all across the hematopoietic cell transplantation and cellular therapy ecosystem","volume":"28","author":"Auletta","year":"2022","journal-title":"Transplant Cell Ther"}],"container-title":["Mayo Clinic Proceedings: Innovations, Quality & Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454825000931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454825000931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T21:24:11Z","timestamp":1769808251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2542454825000931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2542454825000931"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2025.100682","relation":{},"ISSN":["2542-4548"],"issn-type":[{"value":"2542-4548","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Operationalizing Access for Chimeric Antigen Receptor T cell Therapies: A Cross-functional Perspective","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings: Innovations, Quality & Outcomes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2025.100682","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research.","name":"copyright","label":"Copyright"}],"article-number":"100682"}}